Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 15, 2012, Pages 2143-2156

  Montemurro, Filippo ^a   Rossi, Valentina ^a   Geuna, Elena ^a   Valabrega, Giorgio ^a   Martinello, Rossella ^a   Milani, Andrea ^a   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Aromatase inhibitors; Endocrine resistance; Everolimus; Fulvestrant; Gefitinib; Lapatinib; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; GONADORELIN AGONIST; HORMONE RECEPTOR; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MEGESTROL ACETATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TAMOXIFEN; TRASTUZUMAB;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CLINICAL EFFECTIVENESS; DIARRHEA; DOSE RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; DYSGEUSIA; EPISTAXIS; FATIGUE; FEVER; HEMATOLOGIC DISEASE; HOT FLUSH; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; NAUSEA; PIASTRINOPENIA; POSTMENOPAUSE; PROTEIN EXPRESSION; PRURITUS; RASH; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; POSTMENOPAUSE; RECEPTOR, ERBB-2;

EID: 84866518703     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.725723     Document Type: Review

References (82)

1. Bosetti C, Bertuccio P, Levi F, et al. The decline in breast cancer mortality in Europe: an update (to 2009). Breast 2012;21:77-82
2. Cady B, Michaelson JS, Chung MA. The "tipping point" for breast cancer mortality decline has resulted from size reductions due to mammographic screening. Ann Surg Oncol 2011;18:903-6
3. Winkfield KM, Harris JR. Effective local therapy and long-term survival in breast cancer. Oncology (Williston Park) 2009;23:669-75
4. Montemurro F, Redana S, Valabrega G, et al. Controversies in breast cancer: adjuvant and neoadjuvant therapy. Expert Opin Pharmacother 2005;6:1055-72 (Pubitemid 40959471)
5. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2004;100:44-52
6. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005;123:541-6 (Pubitemid 40418549)
7. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-52
8. Carlson RW, Theriault R, Schurman CM, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 2010;28:3917-21
9. Bartsch R, Bago-Horvath Z, Berghoff A, et al. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer 2012;48(13):1932-8
10. Beatson GT. On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7
11. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998;4:527-34 (Pubitemid 28193549)
12. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003;9:1980-9 (Pubitemid 36687616)
13. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84 (Pubitemid 28455101)
14. Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003;CD002747
15. Arpino G, De AC, Giuliano M, et al. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. Oncology 2009;77(Suppl 1):23-37
16. Arpino G, Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine Rev 2008;29:217-33 (Pubitemid 351519691)
17. Muss HB, Wells HB, Paschold EH, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis-a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988;6:1098-106
18. Harvey HA. Aromatase inhibitors in clinical practice: current status and a look to the future. Semin Oncol 1996;23:33-8 (Pubitemid 26320225)
19. Nabholtz JM, Mouret-Reynier MA, Durando X, et al. Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. Expert Opin Pharmacother 2009;10:1435-47
20. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142-52 (Pubitemid 28419067)
21. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61 (Pubitemid 28135586)
22. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357-66 (Pubitemid 32642188)
23. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: results of a Phase III Randomized Double-Blind Trial. J Clin Oncol 2000;18:1399-411 (Pubitemid 30205385)
24. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9 (Pubitemid 46606358)
25. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57
26. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-67
27. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883-90
28. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009;CD003370
29. Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39:2318-27 (Pubitemid 37214856)
30. Llombart-Cussac A, Ruiz A, Anton A, et al. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer. Cancer 2011;118:241-7
31. Possinger K. Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer. Expert Opin Pharmacother 2004;5:2549-58 (Pubitemid 39646516)
32. Kabos P, Borges VF. Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer. Expert Opin Pharmacother 2010;11:807-16
33. Robertson JF. Fulvestrant (Faslodex) - how to make a good drug better. Oncologist 2007;12:774-84 (Pubitemid 47328221)
34. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-38 (Pubitemid 36828445)
35. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13 (Pubitemid 41079798)
36. Robertson JF, Erikstein B, Osborne KC, et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet 2004;43:529-38 (Pubitemid 38858305)
37. Robertson JF, Semiglazov V, Nemsadze G, et al. Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer 2007;43:64-70 (Pubitemid 46054466)
38. Chia S, Gradishar W, Mauriac L, et al. Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: results From EFECT. J Clin Oncol 2008;26:1664-70
39. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-44 (Pubitemid 30350215)
40. Bertelli G, Garrone O, Merlano M, et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005;69:471-7
41. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600
42. Robertson JFR, Lindemann JPO, Llombart-Cussac A, et al. Abstract S1-3: a Comparison of Fulvestrant 500 mg with Anastrozole as First-Line Treatment for Advanced Breast Cancer: Follow-Up Analysis from the 'FIRST' Study. Cancer Res 2011;70:S1-3
43. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-5
44. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-43
45. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93
46. Miller TW, Rexer BN, Garrett JT, et al. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011;13:224
47. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37 (Pubitemid 33674041)
48. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82 (Pubitemid 17231334)
49. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37
50. Schwarzberg LS, Franco SX, Florance A, et al. Lapatinib plus letrozole as first-Line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010;15:122-9
51. Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2- positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012;21:27-33
52. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
53. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007;7:257-68 (Pubitemid 46192173)
54. Hoadley KA, Weigman VJ, Fan C, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007;8:258
55. Osborne CK, Neven P, Dirix LY, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011;17:1147-59
56. Cristofanilli M, Valero V, Mangalik A, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010;16:1904-14
57. Polychronis A, Sinnett HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005;6:383-91 (Pubitemid 40753744)
58. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-70
59. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9- (4,4,5,5,5- pentafluoropentylsulfinyl)- nonyl]estra-1,3,5, (10)-triene- 3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739-46 (Pubitemid 32896496)
60. Bergh J, Jonsson PE, Lidbrink EK, et al. FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone as First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer. J Clin Oncol 2012;30(16):1919-25
61. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012;367:534-44
62. Johnston S, Kilburn LS, Ellis I, et al. Fulvestrant alone or with concomitant anastrozole vs exemestane following progression on non steroidal aromatase inhibitor - first results of the SoFEa trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747) (abstract S2). Eur J Cancer 2012;48:Suppl 3
63. Sheppard K, Kinross KM, Solomon B, et al. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 2012;17:69-95
64. Baselga J, Semiglazov V, van DP, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7
65. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
66. Bachelot T, Bourgier C, Cropet C, et al. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. J Clin Oncol 2012;30(22):2718-24
67. Santen RJ, Song RX, Zhang Z, et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 2005;12:S61-73 (Pubitemid 41395414)
68. Martin LA, Pancholi S, Chan CMW, et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005;12:1017-36 (Pubitemid 41815794)
69. Thurlimann B, Hess D, Koberle D, et al. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004;85:247-54 (Pubitemid 38987259)
70. Johnston SR. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res 2001;7:4376s-87s (Pubitemid 34031583)
71. Barrios C, Forbes JF, Jonat W, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 2012;23:1378-86
72. Montemurro F, Rossi V, Rocca MC, et al. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 2012;118:17-26
73. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32
74. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER-positive primary breast cancer (abstract 82s). Cancer Res 2010;70:Number 24
75. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-804
76. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006;103:7795-800
77. Wang YC, Morrison G, Gillihan R, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011;13:R121
78. Yardley DA, Burris HA III, Clark BL, et al. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer 2011;11:146-52
79. Traina TA, Rugo HS, Caravelli JF, et al. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol 2010;28:628-33
80. Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011;104:1828-35
81. Trinh XB, Sas L, Van Laere SJ, et al. A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncol Rep 2012;27:657-63
82. Isaacs C, Herbolsheimer P, Liu MC, et al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 2011;125:137-43